Caraco Pharmaceutical Laboratory hit record sales -- $81.9 million in the third quarter of 1007 -- and income -- $10.8 million in that same period.
Excerpt:
The increase is primarily due to the launch of
Oxcarbazepine Tablets (oxcarbazepine), which is a generic version of
Trileptal, partially offset by price erosion and product sales mix.
The company generated cash from operations of $24.3
million in the first nine months of the fiscal year vs. $19.7 million a
year earlier.
Read the entire Great Lakes IT Report
here.
Enjoy this story?
Sign up for free solutions-based reporting in your inbox each week.